CN105228641A - 治疗代谢紊乱的方法 - Google Patents

治疗代谢紊乱的方法 Download PDF

Info

Publication number
CN105228641A
CN105228641A CN201480029386.7A CN201480029386A CN105228641A CN 105228641 A CN105228641 A CN 105228641A CN 201480029386 A CN201480029386 A CN 201480029386A CN 105228641 A CN105228641 A CN 105228641A
Authority
CN
China
Prior art keywords
nrg4
levels
individual
metabolic disorder
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480029386.7A
Other languages
English (en)
Chinese (zh)
Inventor
林建谍
王国晓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CN105228641A publication Critical patent/CN105228641A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201480029386.7A 2013-03-21 2014-03-19 治疗代谢紊乱的方法 Pending CN105228641A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804046P 2013-03-21 2013-03-21
US61/804,046 2013-03-21
PCT/US2014/031171 WO2014153385A2 (en) 2013-03-21 2014-03-19 Methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
CN105228641A true CN105228641A (zh) 2016-01-06

Family

ID=51581794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480029386.7A Pending CN105228641A (zh) 2013-03-21 2014-03-19 治疗代谢紊乱的方法

Country Status (6)

Country Link
US (1) US9878010B2 (enExample)
EP (1) EP2976094B1 (enExample)
JP (1) JP6565121B2 (enExample)
CN (1) CN105228641A (enExample)
ES (1) ES2751391T3 (enExample)
WO (1) WO2014153385A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110279860A (zh) * 2019-07-31 2019-09-27 上海交通大学医学院附属瑞金医院 Nrg4作为靶点在制备糖尿病药物中的应用
CN114075272A (zh) * 2020-08-10 2022-02-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744512B1 (en) 2011-08-15 2019-07-03 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
AU2015336954A1 (en) * 2014-10-22 2017-06-08 Katholieke Universiteit Leuven Ku Leuven Research & Development Modulating adipose tissue and adipogenesis
WO2016116477A1 (en) * 2015-01-20 2016-07-28 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
WO2017058828A1 (en) 2015-09-28 2017-04-06 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
WO2020086667A1 (en) * 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005622A1 (en) * 2002-06-03 2004-01-08 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
US20040121326A1 (en) * 2000-04-21 2004-06-24 Daniel Harari Growth factor which acts through erb b-4 rtk
US20050005622A1 (en) * 2003-07-10 2005-01-13 Powell Brian C. Condiment holder
WO2008006922A1 (es) * 2006-07-14 2008-01-17 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina
WO2010138387A2 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of treating chronic neurogenic inflammation using interleukin retargeted endopepidases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
WO2001014415A2 (en) * 1999-08-20 2001-03-01 Chiron Corporation Egfh2 genes and gene products
US6544759B1 (en) * 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121326A1 (en) * 2000-04-21 2004-06-24 Daniel Harari Growth factor which acts through erb b-4 rtk
US20040005622A1 (en) * 2002-06-03 2004-01-08 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
US20050005622A1 (en) * 2003-07-10 2005-01-13 Powell Brian C. Condiment holder
WO2008006922A1 (es) * 2006-07-14 2008-01-17 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina
WO2010138387A2 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of treating chronic neurogenic inflammation using interleukin retargeted endopepidases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUNG ET AL.: "Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis", 《CELL METABOLISM》 *
帕苏普来蒂: "《功能食品、血糖健康与II型糖尿病》", 31 January 2012 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110279860A (zh) * 2019-07-31 2019-09-27 上海交通大学医学院附属瑞金医院 Nrg4作为靶点在制备糖尿病药物中的应用
CN114075272A (zh) * 2020-08-10 2022-02-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法

Also Published As

Publication number Publication date
EP2976094B1 (en) 2019-08-28
EP2976094A4 (en) 2016-09-14
US9878010B2 (en) 2018-01-30
EP2976094A2 (en) 2016-01-27
JP6565121B2 (ja) 2019-08-28
WO2014153385A2 (en) 2014-09-25
WO2014153385A3 (en) 2014-11-13
ES2751391T3 (es) 2020-03-31
JP2016522163A (ja) 2016-07-28
US20160279201A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
JP6565121B2 (ja) 代謝障害を治療する方法
Winbanks et al. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin
Sandri et al. Signalling pathways regulating muscle mass in ageing skeletal muscle. The role of the IGF1-Akt-mTOR-FoxO pathway
JP5421109B2 (ja) 低カルボキシル化／非カルボキシル化オステオカルシンはベータ細胞増殖、インスリン分泌、インスリン感受性、耐糖能を増加させ、体脂肪量を減少させる
Wu et al. DJ-1 maintains energy and glucose homeostasis by regulating the function of brown adipose tissue
Danilova et al. Emerging roles for mesencephalic astrocyte-derived neurotrophic factor (MANF) in pancreatic beta cells and diabetes
Petäistö et al. Lack of collagen XVIII leads to lipodystrophy and perturbs hepatic glucose and lipid homeostasis
Efthymiou et al. Inhibition of AXL receptor tyrosine kinase enhances brown adipose tissue functionality in mice
US20230190689A1 (en) Methods and compositions for inducing brown adipogenesis
JP2010506897A (ja) 脂肪貯蔵と関連した障害を治療する方法
Rehage et al. Transgenic overexpression of pregnancy-associated plasma protein-A increases the somatic growth and skeletal muscle mass in mice
US8383580B2 (en) Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
US20240342244A1 (en) Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease
PT1701978E (pt) Utilização de caderina-t solúvel no tratamento de distúrbios metabólicos
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
CN110913885A (zh) 使用脂肪特异性蛋白27（fsp27）组合物调节游离脂肪酸通量的方法
CN108144060A (zh) 一类通过调控yb-1磷酸化治疗单核细胞趋化蛋白-1参与的疾病的药物及其筛选方法
Alliouachene et al. Uninephrectomy and class II PI3K-C2β inactivation synergistically protect against obesity, insulin resistance and liver steatosis in mice
US20220119511A1 (en) Compositions and methods for treatment of diabetes, obesity, hyper-cholesterolemia, and atherosclerosis by inhibition of sam68
EP1705256A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
Suzuki et al. The F2-Isoprostane: Thromboxane-prostanoid receptor signaling axis drives persistent fibroblast activation in pulmonary fibrosis
US20230174633A1 (en) Methods and compositions for modulating lipid storage in adipose tissue
Abbedissen Characterization of the CEL-MODY mouse–A new disease model for chronic pancreatitis
TW202535392A (zh) 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
TW201519902A (zh) 絲胺酸蛋白酶抑制蛋白：治療β細胞再生之方法及功能

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160106